AMG 319 Lymphoid Malignancy FIH
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
- Status
- COMPLETED
- Phase
- PHASE1
Nonmyeloablative Allogeneic Transplant
- Status
- COMPLETED
- Phase
- NA
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE2
Antiviral Treatment of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE4
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- COMPLETED
- Phase
- PHASE2
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE3
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Tandem Auto-Allo Transplant for Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
- Status
- TERMINATED
- Phase
- PHASE2
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
- Status
- COMPLETED
- Phase
- PHASE1
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
- Status
- COMPLETED
- Phase
- PHASE2